23 June 2021 - Eisai announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor Tazverik 200 mg tablets (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation positive follicular lymphoma (only when standard treatment is not applicable).

This approval is based on the results of a multicenter, open-label, single-arm clinical Phase 2 trial (Study 206) in Japan conducted by Eisai and other studies conducted by Epizyme outside Japan.

Read Eisai press release